24 Oct 2018 I The release and presentation materials are now available.
|10/30/2018||Composition of the Nomination Committee of Orion Corporation|
|10/24/2018||Orion Group Interim Report January-September 2018|
|10/24/2018||Orion and Bayer have completed the phase III trial of darolutamide in patients with non-metastatic castration-resistant prostate cancer - The primary endpoint was met|
|9/19/2018||Changes in responsibility areas of the Orion Group Executive Management Board|
|11/1/2018||Orion Research Foundation grants million euros for research in 2019|
|10/24/2018||Orion and Amgen to collaborate on the commercialisation of AMGEVITA® (biosimilar adalimumab) in Finland|
|10/10/2018||Publishing of Orion Corporation's Interim Report for January-September 2018 on 24 October 2018|
|9/17/2018||Creation of novel medicines and better patient care for the future in an ecosystem|
The product and service portfolio of Orion includes a variety of human pharmaceuticals, veterinary drugs, APIs and contract manufacturing.
Orion’s pharmaceutical innovations are created within its R&D organisation. The organisation employs top professionals in the field of drug molecule development and optimisation.
One key area of Orion's business is Critical Care. Our portfolio includes Simdax® for acute heart failure and Precedex® and Dexdor® for sedation. Read more about Orion's proprietary products and other human pharmaceuticals.
Orion is the largest employer in the Finnish pharmaceutical industry. It is considered to be a good and reliable employer, which is also indicated by its lower-than-average employee turnover.